178
Participants
Start Date
January 20, 2021
Primary Completion Date
April 30, 2025
Study Completion Date
December 31, 2026
Neoadjuvant treatment
PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Zhongshan hospital, Shanghai
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai Public Health Clinical Center
OTHER_GOV
RenJi Hospital
OTHER
Shenzhen University General Hospital
OTHER
Sir Run Run Shaw Hospital
OTHER
Tang-Du Hospital
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
First Hospital of China Medical University
OTHER
Eastern Hepatobiliary Surgery Hospital
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Peking Union Medical College Hospital
OTHER
Meng Chao Hepatobiliary Hospital of Fujian Medical University
OTHER
The First Affiliated Hospital of University of Science and Technology of China
OTHER
Cancer Hospital of Guangxi Medical University
OTHER
Tongji Hospital
OTHER
Zhejiang Provincial People's Hospital
OTHER
The Second Affiliated Hospital of Kunming Medical University
OTHER
Sichuan Provincial People's Hospital
OTHER
Taizhou Hospital
OTHER
Shaoxing People's Hospital
OTHER
The First Hospital of Hebei Medical University
OTHER
Shanghai Zhongshan Hospital
OTHER